CD73 Antibody Epitope Binding for Enzymatic Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibodies targeting CD73 lack clarity in their mode of action, as they often do not purely block the enzymatic activity of CD73, and existing assays struggle to distinguish true CD73 function-blocking antibodies from false positives, complicating the evaluation of their effectiveness in inhibiting tumor growth and metastasis.
Innovation Solution
Development of antibodies that specifically bind to an epitope on CD73, inhibiting its enzymatic activity without binding to Fcγ receptors, allowing for pure blocking of CD73 enzymatic activity and avoiding ADCC, with a focus on allosteric inhibition and high-affinity binding to both substrate-bound and non-substrate-bound CD73 forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies are used to target CD73, then CD73 enzymatic activity can be inhibited, but the mode of action remains unclear due to Fcγ receptor binding and ADCC effects
Solution Approach 1:
The patent extracts and removes the Fc region from the antibody structure, creating F(ab')2 fragments that retain CD73 binding capability while eliminating Fcγ receptor interaction. This separation allows independent evaluation of CD73 blocking activity without confounding ADCC effects, directly resolving the mechanism complexity issue while maintaining inhibition effectiveness.
Solution Approach 2:
The antibody molecule is segmented into distinct functional regions: the Fab regions retain antigen binding specificity for CD73, while the Fc region (source of Fcγ receptor binding) is removed. This segmentation enables selective preservation of the desired blocking function while eliminating the unwanted immunomodulatory effects, simplifying mechanism interpretation.
2Measurement precision
If existing antibodies bind to CD73, then they may block enzymatic activity, but it is difficult to distinguish true function-blocking antibodies from false positives
Solution Approach 1:
The patent introduces F(ab')2 fragments as an intermediary tool that binds specifically to CD73 without triggering Fcγ receptor-mediated effects. This intermediary enables direct measurement of enzymatic blocking activity in isolation, serving as a clean readout system that eliminates the confounding variables present in whole antibody assays, thereby improving measurement precision while reducing assay complexity.
Solution Approach 2:
The patent creates a simplified copy of the antibody's antigen-binding function using F(ab')2 fragments, which replicate the CD73 binding and blocking capabilities without the Fc region. This functional copy allows for cleaner assessment of true blocking activity, distinguishing genuine function-blocking antibodies from false positives more easily.
3Object-affected harmful factors
If antibodies bind to CD73 on tumor cells, then they may inhibit tumor growth, but Fc-mediated effects complicate the therapeutic mechanism
Solution Approach 1:
The Fc region, which mediates unwanted Fcγ receptor binding and ADCC effects, is extracted and removed from the antibody structure. The resulting F(ab')2 fragments retain the ability to bind and block CD73 on tumor cells, thereby maintaining anti-tumor activity while eliminating Fc-mediated harmful effects, achieving cleaner therapeutic mechanism.
4Reliability
If CD73 enzymatic activity is blocked, then adenosine production is reduced and T cell activity is enhanced, but existing antibodies lack pure blocking capability
Solution Approach 1:
F(ab')2 fragments serve as an intermediary that provides pure CD73 blocking function without Fc-mediated immunomodulation. This intermediary enables precise measurement and achievement of the desired effect (reduced adenosine production and enhanced T cell activity) by eliminating confounding variables, thereby improving both reliability and measurement precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antibodies effectively neutralize CD73 enzymatic activity, providing potent inhibition of CD73-mediated immunosuppression in the tumor microenvironment, enhancing T cell activity and potentially inhibiting tumor growth and metastasis with improved pharmacological properties.
Implementation Method 1
an antibody that specifically binds a human CD73 polypeptide and that neutralizes the enzymatic activity of cellular human CD73
Implementation Method 2
CD73 catalyzes the conversion of AMP to adenosine... these antibodies effectively neutralize CD73 enzymatic activity, providing potent inhibition of CD73-mediated immunosuppression
Data Source
AI summary
This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5′ nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.